[Fibronostics to Present LIVERFASt Data at DDW 2026](/content/fibronostics-to-present-liverfast-data-at-ddw-2026/index.html)

Fibronostics to Present LIVERFASt Data at DDW 2026

Fibronostics is pleased to share that Dr. Mona Munteanu, Chief Scientific Officer at Fibronostics, will be presenting new data on

Fibronostics is excited to announce our participation in the MASH-TAG 2026 Conference, held from January 8-10, 2026, in beautiful Deer

At Fibronostics, our mission is built on a foundation of precision and trust. We are proud to announce that we

Fibronostics is thrilled to announce its participation in the AASLD Liver Meeting 2025, the world’s leading conference dedicated to advancing

We’re excited to announce that Fibronostics has completed the acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced

On June 11-13, Fibronostics had the privilege of participating in the THASL 2025 Annual Conference, hosted by the Thai Association

In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4

Fibronostics is pleased to announce its participation in the THASL 2025 Annual Conference, hosted by the Thai Association for the Study of the

Fibronostics is now officially SOC 2 Type II compliant! This compliance reflects our deep commitment to keeping your data and

We did it again! Fibronostics is proud to announce that we have successfully renewed our ISO 27001:2022 certification for.